Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPORT

02 FEB 14 PM 4: 03

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name		<u></u>	
Akin, Gump, Strauss, Hauer & Feld, L.L.P.			
2. Address			
1333 New Hampshire Avenue, NW	**		
3. Principal Place of Business (if different from line 2)			
City: Washington State/Zip (or	Country) DC 20036		
4. Contact Name Telephone	E-mail (optional) 5.	Senate ID #	
Donald R. Pongrace 202-887-4000		682-86	
7. Client Name		House ID #	
Pfizer, Inc.		317840	
TYPE OF REPORT 8. Year 2001 Midyear	(January 1-June 30) OR Year End (J	uly 1-Dec	
9. Check if this filing amends a previously filed version of this report			
<u> </u>	·,··		
10. Check if this is a Termination Report ☐ → Terminati	ion Date 11. N	o Lobbyii	
INCOME OR EXPENSES – Complete Either Line 12 OR Line 13			
12. Lobbying Firms	13. Organizations		
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities f were:	for this rep	
Less than \$10,000	Less than \$10,000		
\$10,000 or more 🔀 🖘 \$ 120,000	\$10,000 or more		
Income (nearest \$20,000)		ome (nearest	
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of		
	☐ Method A. Reporting amounts using L	Method A. Reporting amounts using LDA defini	
	Method B. Reporting amounts under section 603 Internal Revenue Code		
	Method C. Reporting amounts under so Internal Revenue Code	ection 162	
Signature			
·			
Printed Name and Title Donald R. Pongrace, Partner			

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P.	Client Name Pfizer, Inc.
LOBBYING ACTIVITY. Select as many codes as necessar engaged in lobbying on behalf of the client during the reporti information as requested. Attach additional page(s) as needed	ng period. Using a separate page for each cod
15. General issue area codeTRA (one per page)	
16. Specific lobbying issues Potential legislation or regulation regarding use of certa	in antihistamines by operators of commercial ve
17. House(s) of Congress and Federal Agencies contacted U.S. House of Representatives U.S. Senate U.S. Department of Transportation	☐ Check if None
18. Name of each individual who acted as a lobbyist in this i	ssue area
Name	Covered Official Position (if applicable)
Charles W. Johnson, IV	
J. Robert Joyce	
Susan H. Lent	
Donald R. Pongrace	
Henry A. Terhune	
19. Interest of each foreign entity in the specific issues listed on line	e 16 above 🔲 Check if None
Signature	Date February 14, 200
Printed Name and Title Donald R. Pongrace, Partner	· · · · · · · · · · · · · · · · · · ·

Registrant Name	Akin, Gump, Strauss, Hauer & Feld, L.L.P.	Client Name Pfizer, Inc.
engaged in lobby		ry to reflect the general issue areas in which the ing period. Using a separate page for each coded.
15. General issue	area code <u>HCR</u> (one per page)	
16. Specific lobb	ying issues	
Medicare Processing Companies		uding S. 1135; international issues affecting
U.S. House o	Congress and Federal Agencies contacted f Representatives	☐ Check if None
U.S. Senate U.S. Departm	ent of Health & Human Services	
18. Name of each	n individual who acted as a lobbyist in this i	ssue area
	Name	Covered Official Position (if applicable)
Stacy Carlson	Bill Paxon	
Smith W. Dav	vis Donald R. Pongrace	
Anthony Foti	Paul G. Scolese	
Gary A. Hein	ıberg	
Jorge Lopez,	Jr.	
Michael J. Pa		
P. Vincent Lo	Voi	***************************************
Thaddeus Bu	rns	
19. Interest of each	foreign entity in the specific issues listed on line	e 16 above
Signature	An Prysau	Date February 14, 200
Printed Name and T	Title Donald R. Pongrace, Partner	